Nathan Pliam
Partner @ Decheng Capital
San Francisco, United States
Nathan Pliam is a seed investor at Decheng Capital in San Francisco focused on Health Care and Biotechnology. Nathan Pliam is the Founder of Ancora Heart. He previously worked at Bay City Capital LLC as a Venture Partner. Nathan Pliam attended Stanford University School of Medicine.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Nathan Pliam invests in
Stages Nathan Pliam invests in
Countries Nathan Pliam invests in
Investment Focus
Industry
- Health Care 1 (25%)
- Biotechnology 1 (25%)
- Pharmaceutical 1 (25%)
- Health Diagnostics 1 (25%)
Stage
- Seed 1 (25%)
- Series A 1 (25%)
- Series B 1 (25%)
- Series C 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nevro
|
Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza systemis the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro. | Series C / Mar 07, 2013 | |
|
Nevro
|
Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza systemis the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro. | Series B / Jul 19, 2011 | |
|
Nevro
|
Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza systemis the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro. | $21.8M / Series A / Sep 10, 2008 | |
|
Nevro
|
Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza systemis the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro. | $5.5M / Seed / Dec 04, 2006 |
Co-Investors
About Decheng Capital
Decheng Capital is an investment firm that provides capital and strategic support to life science companies with revolutionary technologies and growth-stage healthcare companies with a strong market presence. It is a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successfulcompanies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of the healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.
Decheng Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dan Zabrowski
Venture Partner
|
|||
Min Cui
Founder and Managing Director
|
|||
Dayton Misfeldt
Partner
|
|||
|
Nathan Pliam
Partner
|
|||
Victor Tong
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Nathan Pliam invest in?
Nathan Pliam invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Nathan Pliam last invest?
The most recent investment recorded for Nathan Pliam closed in Mar 2013. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
